Back to Search
Start Over
Clinical outcomes of Chronic Myeloid Leukaemia (CML) patients on asciminib through the Managed Access Program (MAP) in Australia
- Publication Year :
- 2022
- Publisher :
- US : American Society of Hematology, 2022.
-
Abstract
- Asciminib is the first tyrosine kinase inhibitor (TKI) to Specifically Target the ABL Myristoyl Pocket (STAMP). In the ASCEMBL Phase 3 randomised study comparing asciminib to bosutinib in patients with CML in chronic phase (CP) after ³2 prior TKIs, asciminib demonstrated superior efficacy and tolerability vs bosutinib (major molecular response (MMR) rate at week 96: 37.6% vs 15.8%, treatment discontinuation 7.7% vs 26.3%) (Rea et al, EHA 2022). Here we present the real-world clinical outcomes of TKI-resistant/ intolerant CML patients in Australia who received asciminib through a MAP approved by Novartis.
- Subjects :
- Immunology
Cell Biology
Hematology
Biochemistry
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....8fbeb9274c847e80c9e4b44851795fd5